PROLX PHARMACEUTICALS DESIGNATED CORPORATE PARTNER IN $5.6 MILLION GRANT

ProlX Pharmaceuticals announced today that it has been appointed Corporate Partner for a consortium of four leading research institutions that has received a $5.6 million National Cooperative Drug Discovery Group (NCDDG) award from the National Cancer Institute. The research sites include the M.D. Anderson Cancer Center, the Burnham Institute Cancer Research Center, the University of Pittsburgh, and St. Jude Children's Research Hospital.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1121647XSL_NEWSML_TO_NEWSML_WEB.xml)